BIOETHICS LTD financial data

Location
Ogden, UT
Fiscal year end
31 December
Latest financial report
10-K - Q4 2024 - 13 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.2 % +2556%
Debt-to-equity -101 % -1.17%
Return On Equity 20.5 % +55.8%
Return On Assets -1.68K % +94.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.6M shares +217%
Common Stock, Shares, Outstanding 3.34M shares +194%
Entity Public Float 293K USD +971%
Common Stock, Value, Issued 3.34K USD +194%
Weighted Average Number of Shares Outstanding, Basic 1.49M shares +31.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
General and Administrative Expense 123K USD +143%
Operating Income (Loss) -123K USD -143%
Nonoperating Income (Expense) -50K USD -4.78%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -177K USD -82.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -177K USD -82.1%
Earnings Per Share, Basic 0 USD/shares -25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.7K USD +10526%
Assets, Current 14.7K USD +10526%
Assets 14.7K USD +10526%
Accounts Payable, Current 193K USD +57.5%
Accrued Liabilities, Current 109K USD +21.7%
Liabilities, Current 946K USD +21.8%
Liabilities 946K USD +21.8%
Retained Earnings (Accumulated Deficit) -1.45M USD -13.8%
Stockholders' Equity Attributable to Parent -931K USD -20%
Liabilities and Equity 14.7K USD +10526%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.9K USD -93.6%
Net Cash Provided by (Used in) Financing Activities 5.85K USD +95%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 3.34M shares +194%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.7K USD +10526%
Deferred Tax Assets, Valuation Allowance 326K USD +12.8%
Deferred Tax Assets, Operating Loss Carryforwards 298K USD +14.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Additional Paid in Capital 520K USD +3.96%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 54.1K USD +15.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%